OncoChoice-guided chemotherapy for metastatic non-small cell lung cancer (second-line and beyond)

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-arm, Simon two-stage pilot enrolling adults with metastatic (primarily Stage IV) NSCLC who have received at least one prior systemic therapy. After consent, patients undergo tumor biopsy or malignant fluid collection and samples are sent within 24 hours to OncoOptima for OncoChoice drug-response testing. Treating physicians use OncoChoice results alongside NCCN dosing guidelines to select FDA-approved chemotherapy agents such as docetaxel, paclitaxel, gemcitabine, pemetrexed, or vinorelbine. Patients receive standard-of-care chemotherapy with additional testing or therapies allowed at the treating provider's discretion. The study will monitor treatment response and safety to determine whether the OncoChoice-guided approach merits further study.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years of age at time of consent
* ECOG performance status score of ≤2
* Advanced non-small cell lung cancer to meet histologically confirmed Stage IV NSCLC documented by biopsy.
* Patients have received at least 1 prior line of systemic therapy for Stage IV NSCLC, including but not limited to targeted therapy, and are currently candidates for 2L or later SOC chemotherapy. Exceptionally, patients with Stage III NSCLC who have received at least 1 line of systemic therapy may be considered eligible, pending principal investigator approval.
* Demonstrates adequate organ function; labs must be within treatment parameters for the individual institutional treatment plans for specific therapeutic agents. All screening labs to be obtained within 30 days prior to registration.
* Must have not received any cancer treatment for at least 2 weeks.
* Must be a candidate for small molecule drug treatment.
* Participants or their LAR must be able to provide written informed consent and HIPAA authorization for release of personal health information, via an approved UIC Institutional Review Board (IRB) informed consent form and HIPAA authorization.
* Women of childbearing potential must not be pregnant or breast-feeding. A negative serum or urine pregnancy test is required per institutional practice guidelines.
* As determined at the discretion of the enrolling physician or protocol designee, ability of the subject to understand and comply with study procedures for the entire length of the study.

Exclusion Criteria:

* Active infection requiring systemic therapy within 7 days of enrollment.
* Uncontrolled HIV/AIDS or active viral hepatitis (e.g., HBV, HCV)
* Any ongoing significant toxicity resulting from prior anticancer therapy that, as determined by the treating provider, has the potential to interfere with the safety or efficacy assessment of this investigational regimen.
* ECOG performance status score \>2
* Clinically significant lung, heart, or autoimmune disease
* Life expectancy \<12 weeks
* Prior solid organ or bone marrow transplant
* Antibiotics, live vaccines or other type of surgery within 4 weeks prior intervention treatment
* Pregnant or nursing
* Any prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of this investigational regimen, as determined by the treating provider.
* Any mental or medical condition that prevents the patient from giving informed consent or participating in the trial.
* Another major comorbidity, as determined by treating provider.

Where it's running

• University of Illinois Cancer Center
  Chicago, Illinois, United States Recruiting

Study contacts

• Principal investigator: Frank Weinberg, MD, PhD — University of Illinois Chicago
• Study coordinator: Frank Weinberg, MD, PhD
• Email: fweinb1@uic.edu
• Phone: (312) 413-7494

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519

  This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.

  Recruiting at 2 sites Phase 1 Aktis Oncology, Inc. · Miami, Florida and 1 other locations · NCT07887971

• SumMET: Targeted radioligand therapy for c-MET–positive solid tumors

  This first‑in‑human study tests the safety and potential effectiveness of a radioligand therapy called [225Ac]Ac-FL-261 in adults with advanced or metastatic solid tumors that overexpress c-MET.

  Recruiting at 2 sites Phase 1/2 Full-Life Technologies UK Limited · Minneapolis, Minnesota and 1 other locations · NCT07873450

• SI-B036 safety test in advanced and metastatic solid tumors

  This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.

  Recruiting at 4 sites Phase 1 SystImmune Inc. · New Haven, Connecticut and 6 other locations · NCT07857616

• YSCH-01 Nebulized Therapy for Lung Metastases in NSCLC and Advanced Solid Tumors

  A first-in-human, early-phase study tests a nebulized therapy called YSCH-01 to see if it is safe and shows any signs of benefit for adults with NSCLC or other cancers that have spread to the lungs.

  Recruiting Early Phase 1 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing · NCT07793500

• NXP900 with Lorlatinib in ALK-positive NSCLC

  This study tests whether adding NXP900 to lorlatinib helps people with ALK-positive non-small cell lung cancer who have already received prior therapy.

  Recruiting Phase 1 Nuvectis Pharma, Inc. · Fairfax, Virginia · NCT07784959

• First-line treatment with pembrolizumab, pemetrexed, and platinum with or without zoldonrasib for metastatic non-squamous NSCLC

  This trial tests whether adding zoldonrasib to standard pembrolizumab and platinum chemotherapy helps people with untreated metastatic non-squamous NSCLC that has a RAS G12D mutation.

  Recruiting at 4 sites Phase 3 Revolution Medicines, Inc. · Anchorage, Alaska and 3 other locations · NCT07777822

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.